Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - IMMUNE PHARMACEUTICALS INC | exhibit1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | September 5, 2011 |
EpiCept Corporation
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 000-51290 | 52-1841431 |
|
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 777 Old Saw Mill River Rd., Tarrytown, New York | 10591 | |
|
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 914-606-3500 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On September 7, 2011, EpiCept Corporation (the "Company") announced that Nasdaq OMX Stockholm AB has approved the Company’s request for a primary listing of its common stock on the Nasdaq OMX Stockholm Exchange. The Company previously had a secondary listing on Nasdaq OMX Stockholm. EpiCept sought the change in status in recognition of the Company’s large Swedish shareholder base and the historical trading volume of the Company’s common stock on the Exchange. The change in status became effective September 5, 2011 and does not affect the Company's short name and order book I.D. on the Exchange or the trading of its common stock on the Nasdaq Capital Market. The Company will continue to make quarterly and other regulatory filings with the Securities and Exchange Commission.
Item 9.01 Financial Statements and Exhibits.
99.1 Press release of EpiCept Corporation, dated September 7, 2011.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EpiCept Corporation | ||||
| September 9, 2011 | By: |
Robert W. Cook
|
||
|
|
||||
| Name: Robert W. Cook | ||||
| Title: Chief Financial Officer | ||||
Exhibit Index
| Exhibit No. | Description | |
|
|
|
|
|
99.1
|
Press release of EpiCept Corporation, dated September 7, 2011. |